Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo To Analyze Protein PTMs for Boehringer Ingelheim

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies said today that it will use its mass spectrometry platform to quantitatively analyze post-translational modifications of proteins for Boehringer Ingelheim.
Kinaxo, a spinout of the Max-Planck Institute of Biochemistry based in Martinsried, Germany, will use its Cellular Target Profiling technology to study the effects of different compounds on proteome-wide signal transduction pathways for the drugmaker.
In the initial phase of the two-year agreement, the company will conduct two studies that will provide “a detailed and comprehensive picture” of in vivo mode of action in cultured cells or in animal tissue.
One study will analyze cell lines to measure the effects of an enzyme inhibitor on the acetylation status of the cellular proteome.
In a second study, Kinaxo will use its phosphoproteomics technology to compare neural tissues of wild-type and genetically modified mouse strains to identify differences in signal transduction pathway activation with the goal of identifying new drug targets.
The company’s PTM analysis service combines its mass spectrometry platform with stable isotope labeling by amino acids in cell culture, or SILAC, which was developed at Max-Planck.
Financial terms of the agreement were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.